References

CHARACTERIZE CANCER

Methylation signatures using
cfDNA can accurately distinguish neuroendocrine prostate cancer (NEPC) from prostate adenocarcinoma (PAC), often missed through routine clinical care.¹

Apply methylation signature
to stratify patients:

Evaluate patient response to
ARSi based on cancer subtypes¹:

Median overall survival after metastasis¹


ARSi, androgen receptor signaling inhibitor; cfDNA, cell-free DNA; CRPC, castration-resistant prostate cancer.

Methylation
signatures can lead to
more accurate personalized medicine and predict patient response to treatment.¹

Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma